On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B.

JHEP Rep · 2023 · PMC10494462 · PMID 37701335

Europe PMC DOI

hedged sentence

0.6200

closest p · 12.4× alpha

0.6200

boldest claim

The sentences

did not reach statistical significancep = 0.62not close (p > 0.1)

Similarly, among non-Asians, risk of HCC was lower in patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide when compared to entecavir, but these differences did not reach statistical significance (0.23 in tenofovir alafenamide vs. 0.58 in entecavir per 100 person-years, p = 0.62; 0.35 in tenofovir disoproxil fumarate vs. 0.58 in entecavir per 100 person-years, p = 0.15).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.